MD Biosciences and Becton Dickinson sign Agreement For the Distribution of Streptococcus Cell Wall Extract, PG-PS.

St Paul, MN, April 10, 2005 - MD Biosciences, an international provider of inflammatory research products and pre-clinical services, announces today that it has entered into an agreement with BD (Becton Dickinson and Company) Lee Laboratories to sell PG-PS (peptidoglycan-polysaccharide polymer streptococcus cell wall extract) products. BD Lee Laboratories approached MD Biosciences for its established leadership in inflammations research and the agreement will serve to expand and strengthen MD Biosciences inflammatory research product line.

PG-PS is purified polymers produced from the cell walls of Streptococcus pyogenes Group A. The use of these polymers in in vivo models of disease induces an acute and chronic inflammatory reaction, which can evolve into a remittent, arthritic response that is representative of naturally caused inflammatory disorders. “The addition of PG-PS will complement our focused product line of inflammatory research reagents and will provide an additional resource for clients who are engaged in in vivo models of disease for their drug discovery efforts” commented Amy Clausen, Marketing Manager for MD Biosciences.

PG-PS is a valuable resource to researchers involved in inflammatory drug discovery. The induction of a biphasic inflammatory response in disease models is used for the evaluations and studies of anti-inflammatory drugs and therapies for inflammatory diseases such as arthritis, granulomatous enterocolitis (resembling Crohn’s disease), and others.

About MD Biosciences
MD Biosciences (www.mdbiosciences.com) is an international biotech company providing the most advanced products and pre-clinical services for pharmaceutical and biotechnology companies engaged in inflammations research. With specialized laboratories located in Minnesota, Glasgow, and Israel, our panel of internationally recognized experts provides in-depth expertise and technologies to tackle problems and provide total solutions to the inflammatory disease drug discovery market.

About BD Lee Laboratories
Lee Laboratories, a fully owned subsidiary of BD (Becton Dickinson), offers reagents and services for diagnostics and inflammation research. BD is a medical technology company that serves life science researchers, clinical laboratories, and the healthcare industry.

————

The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.